阿戈梅拉丁作为辅助治疗与SSRI或SNRIs治疗主要抑郁症:一个多中心,双盲,随机,安慰剂控制的试验
Yumeng Ju1,2, Wenwen Ou1,2, Haoran Chen3
1Department of Psychiatry, and National Clinical Research Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, Hunan, 410011, China.
BMC medicine
|March 4, 2025
概括
阿戈梅拉丁增量并没有显著改善对SSRI/SNRIs无反应的大型抑郁症 (MDD) 患者的治疗结果. 然而,当与这些抗抑郁药物结合使用时,阿戈梅拉丁显示出良好的安全性.
科学领域:
- 精神病学是一个精神病学.
- 临床药理学 临床药理学
- 神经科学是一个神经科学.
背景情况:
- 大型抑郁症 (MDD) 往往对传统抗抑郁药的反应有限.
- 阿戈梅拉丁具有独特的机制,正在探索用于增强标准治疗.
- 本研究侧重于对SSRI或SNRIs反应不足的MDD患者.
研究的目的:
- 评估阿戈梅拉丁作为附加治疗与安慰剂的疗效.
- 评估MDD患者的增强效应,这些患者之前对SSRI/SNRIs没有反应.
- 为了确定阿戈梅拉丁是否可以改善抑郁症的严重程度和缓解率.
主要方法:
- 一个为期8周的多中心,双盲,随机,安慰剂对照试验.
- 参与者与SSRI/SNRIs一起接受了阿戈梅拉丁或安慰剂.
- 抑郁症的严重程度使用汉密尔顿抑郁症量表 (HAMD-17) 进行测量.
主要成果:
- 在agomelatine和安慰剂组之间在8周内没有观察到HAMD-17得分减少的显著差异.
- 二次结果,包括缓解和响应率,也显示没有显著的组间差异.
- 在agomelatine和安慰剂组之间,不良事件是可比的.
结论:
- 对于那些对SSRI/SNRIs无反应的MDD患者来说,阿戈梅拉丁增剂没有产生显著的益处.
- 阿戈梅拉丁耐受性很好,在这个患者群体中表现出良好的安全性.
- 可能需要进一步的研究来确定特定的患者亚组,这些患者可能会从阿戈梅拉丁增强中受益.
相关概念视频
01:23Antidepressant Drugs: MAOIs and Other Agents
175
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
175
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
273
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
273
01:23Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
202
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
202
01:25Antidepressant Drugs: Overview
346
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
346
01:17Sedatives and Hypnotics Drugs: Miscellaneous Agents
143
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
143
01:21G-protein Coupled Receptors
114.3K
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
114.3K